<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2a3303f1-eee7-4c07-9532-e153be149369"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TOLSURA<sup>®</sup> safely and effectively.  See full prescribing information for TOLSURA<sup>®</sup>.<br/>
      <br/> TOLSURA<sup>®</sup> (itraconazole capsules), for oral use<br/> Initial U.S. Approval:  1992</title>
   <effectiveTime value="20250423"/>
   <setId root="306352d1-9d5a-49ad-b72d-893b99546861"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="867220261"/>
            <name>Mayne Pharma Commercial LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="756003745"/>
                        <name>Mayne Pharma International Pty Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-462" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-462" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118812386"/>
                        <name>Catalent Greenville, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-462" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-462" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-462" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d337d7b8-c9fb-47a5-b983-7e1e784f0c8a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20241031"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51862-462" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tolsura</name>
                        <formCode code="C42936" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, GELATIN COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Itraconazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="87Y6436BKR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="588X2YUY0A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLENE CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="65"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="304NUG5GF4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ITRACONAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="304NUG5GF4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ITRACONAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-462-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181211"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="8" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-462-88" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200901"/>
                                    <high value="20240229"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="8" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-462-08" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20181211"/>
                                    <high value="20240229"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208901" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181211"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>Light blue</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">i;65</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="504c8640-5860-40f5-9c1d-0d2509a28d63"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="underline">Congestive Heart Failure</content>
                                 <br/>  TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. If signs or symptoms of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit-risk of continuing treatment. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S6">6</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="underline">Drug Interactions</content>
                              </content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>
                                    <content styleCode="bold">Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with TOLSURA because plasma concentrations of such drugs are increased. (<linkHtml href="#S4.1">4.1</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment. (<linkHtml href="#S4.1">4.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Co-administration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (<linkHtml href="#S4.1">4.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. (<linkHtml href="#S4.1">4.1</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</content>
                                 </item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="798f08c6-27da-45af-8270-23cf4ecdb252"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="underline">Congestive Heart Failure</content>
                                 <br/>  TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. If signs or symptoms of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit and risk of continuing treatment <content styleCode="italics">[</content>see <content styleCode="italics">
                                    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="585e1724-886d-45b4-9502-a793fc36e0ab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="underline">Drug Interactions</content>
                              </content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>
                                    <content styleCode="bold">Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with TOLSURA because plasma concentrations of such drugs are increased, which may also increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>
                                    </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased plasma concentrations of some of these drugs caused by co-administration with TOLSURA can lead to QT prolongation and/or ventricular tachyarrhythmias, including occurrences of <content styleCode="italics">torsades de pointes</content>, a potentially fatal arrhythmia [see <content styleCode="italics">
                                          <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>
                                       </content> and <content styleCode="italics">
                                          <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</content>
                                 </item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="104c70f4-a078-4f7b-bf3d-5d0b575ae8a3"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="85%" align="left" valign="top"/>
                           <col width="15%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Pseudoaldosteronism (<linkHtml href="#S5.4">5.4</linkHtml>)</td>
                                 <td>10/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="102c81e8-c103-484b-afd6-63f9cfbc7b79"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TOLSURA is indicated for the treatment of the following fungal infections in <content styleCode="underline">immunocompromised and non-immunocompromised</content> adult patients:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Blastomycosis, pulmonary and extrapulmonary</item>
                     <item>Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and</item>
                     <item>Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.</item>
                  </list>
                  <paragraph>Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-fungal therapy should be adjusted accordingly</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in <content styleCode="underline">immunocompromised and non-immunocompromised</content> adult patients (<linkHtml href="#S1">1</linkHtml>):</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Blastomycosis, pulmonary and extrapulmonary</item>
                           <item>Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and</item>
                           <item>Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>TOLSURA is not indicated for the treatment of onychomycosis (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>TOLSURA is <content styleCode="bold">NOT</content> interchangeable or substitutable with other itraconazole products (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="59ab6f1b-6b89-4df8-a9c6-59e03410627f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>TOLSURA is not indicated for the treatment of onychomycosis.</paragraph>
                        <paragraph>TOLSURA is NOT interchangeable or substitutable with other itraconazole products due to the differences in the dosing between TOLSURA and other itraconazole products. Therefore, follow the specific dosage recommendations for TOLSURA <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="4f4b98d5-fad0-4f2d-a84a-aece85cb1da4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>TOLSURA must be administered with food.</paragraph>
                  <paragraph>TOLSURA capsules must be swallowed whole. Do not chew, crush or break TOLSURA capsules.</paragraph>
                  <paragraph>Table 1 below describes the recommended dosage for TOLSURA.</paragraph>
                  <table width="75%">
                     <caption>Table 1: Dosage and Administration of TOLSURA</caption>
                     <col width="40%" align="left" valign="top"/>
                     <col width="60%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule">Indications</th>
                           <th styleCode="Rrule">Daily Dosing</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Treatment of Blastomycosis and Histoplasmosis</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Recommended dose</td>
                           <td styleCode="Rrule">130 mg (2 × 65 mg capsules) once daily <br/>  If no obvious improvement, or there is evidence of progressive fungal disease, the dose should be increased in 65 mg increments to a maximum of 260 mg/day (130 mg (2 × 65 mg capsules) twice daily). Doses above 130 mg/day should be given in two divided doses.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Treatment of Aspergillosis</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td rowspan="2" styleCode="Lrule Rrule">Recommended dose</td>
                           <td styleCode="Rrule">130 mg (2 × 65 mg capsules) once daily</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule">260 mg/day (130 mg (2 × 65 mg capsules) twice daily)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Treatment in Life-Threatening Situations</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Although clinical studies did not provide for a loading dose, it is recommended, based on pharmacokinetic data, that a loading dose should be used.</td>
                           <td styleCode="Rrule">A loading dose of 130 mg (2 × 65 mg capsules) three times daily (390 mg/day) is recommended to be given for the first 3 days, followed by the appropriate recommended dosing based on indication. Treatment should be continued for a minimum of three months and until clinical parameters and laboratory tests indicate that the active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Blastomycosis and Histoplasmosis - 130 mg to 260 mg daily (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Aspergillosis - 130 mg to 260 mg daily (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>See full prescribing information for additional dosing for life-threatening situations. (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>TOLSURA must be administered with food. (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Swallow whole. Do not chew crush or break. (<linkHtml href="#S2">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="a659d8cd-5edb-41fc-9184-fbcf5fcd8446"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>TOLSURA (itraconazole capsules) is available in a size 1, hard gelatin capsules with light blue cap and white body, imprinted with "i-65" in black on the cap and containing 65 mg of itraconazole.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules: 65 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="8372929f-7cb9-43a6-8b1b-d05432ba343f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Co-administration with certain drugs that either affect metabolism of itraconazole or whose metabolism is affected by itraconazole. (<linkHtml href="#S4.1">4.1</linkHtml>)</item>
                           <item>Hypersensitivity to itraconazole (<linkHtml href="#S4.2">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="46d00249-05d2-4c74-af63-9531096ac66a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Drug Interactions</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Co-administration of certain drugs that are metabolized by human CYP3A4 substrates are contraindicated with TOLSURA because plasma concentrations of such drugs are increased, which may also increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precaution (5.5)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</item>
                           <item>Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment.</item>
                           <item>Co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</item>
                           <item>Increased plasma concentrations of some of these drugs due to co-administration of TOLSURA can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of <content styleCode="italics">torsade de pointes</content>, a potentially fatal arrhythmia <content styleCode="italics">[</content>see <content styleCode="italics">
                                 <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.2">
                     <id root="fd497cb0-9e3c-46ee-8e76-9c4f95b57160"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Hypersensitivity</title>
                     <text>
                        <paragraph>TOLSURA is contraindicated in patients with known hypersensitivity to itraconazole. There is limited information regarding cross-hypersensitivity between itraconazole and other azole antifungal agents <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="94b62cf4-0d59-4642-b7a5-22aae6cd0be8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Serious hepatotoxicity, including liver failure and death were reported with the use of itraconazole. Discontinue treatment if signs of liver dysfunction occur (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Cardiac Dysrhythmias</content>: Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using certain drugs that are metabolized by human CYP450 enzymes concomitantly with oral itraconazole and/or other CYP3A4 inhibitors. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pseudoaldosteronism</content>: Manifested by the onset or worsening of hypertension, and abnormal laboratory findings. Monitor blood pressure and potassium levels and manage as necessary (<linkHtml href="#S5.4">5.4</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">Peripheral Neuropathy</content>: This has been reported in patients on long-term therapy with itraconazole. Monitor and promptly evaluate neurologic symptoms. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hearing Loss</content>: Reversible or permanent has been reported in patients. Discontinue treatment if hearing loss occurs (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="522b5d5a-d452-4379-ac5f-28e8827cecc4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Congestive Heart Failure</title>
                     <text>
                        <paragraph>TOLSURA can cause or exacerbate congestive heart failure (CHF) <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> For patients with evidence of ventricular dysfunction such as CHF, history or risk factors for CHF, physicians should carefully review the risks and benefits of TOLSURA therapy. These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders. Inform such patients of the signs and symptoms of CHF and monitor carefully for signs and symptoms of CHF during treatment. If signs or symptoms of CHF appear or worsen during administration of TOLSURA, reassess the benefit-risk of continuing treatment.</paragraph>
                        <paragraph>When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was demonstrated. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later.</paragraph>
                        <paragraph>Itraconazole has been associated with reports of CHF, peripheral edema, and pulmonary edema. In post-marketing experience, heart failure was more frequently reported in patients receiving higher total daily doses of itraconazole of 400 mg although there were also cases reported among those receiving lower total daily doses <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, when co-administering itraconazole and calcium channel blockers, monitor carefully for signs and symptoms of CHF during treatment due to an increased risk of CHF. Concomitant administration of TOLSURA and felodipine or nisoldipine is contraindicated <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml> and <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="ce9f3bb9-af78-40f8-91b1-4bd3928bc2ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity</title>
                     <text>
                        <paragraph>Itraconazole has been associated with cases of serious hepatotoxicity, including liver failure and death. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition, and some of these cases developed within the first week of treatment. If clinical signs or symptoms develop that are consistent with liver disease, discontinue treatment and perform testing for liver disease. Continued TOLSURA use or reinstitution of treatment with TOLSURA is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk <content styleCode="italics">
                              <content styleCode="bold">[</content>see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="4639160f-1c14-42e7-9815-6439b076b5a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cardiac Dysrhythmias</title>
                     <text>
                        <paragraph>Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using drugs such as, pimozide, methadone, or quinidine concomitantly with oral itraconazole and/or other CYP3A4 inhibitors. Concomitant administration of these drugs with TOLSURA is contraindicated <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="3716a45e-9483-4307-ad20-7dfd19d5bdf8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Pseudoaldosteronism</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Pseudoaldosteronism, manifested by the onset of hypertension or worsening of hypertension, and abnormal laboratory findings (hypokalemia, low serum renin and aldosterone, and elevate 11-deoxycortisol), has been reported with itraconazole use in the postmarketing setting. Monitor blood pressure and potassium levels and manage as necessary. Management of pseudoaldosteronism may include discontinuation of TOLSURA, substitution with an appropriate antifungal drug that is not associated with pseudoaldosteronism, or use of aldosterone receptor antagonists.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="2c1de254-d8e8-4b42-9a42-e0609a3d9430"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Drug Interaction Potential</title>
                     <text>
                        <paragraph>Itraconazole has a potential for clinically important drug interactions <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1</linkHtml>, <linkHtml href="#S7.2">7.2)</linkHtml>]</content>. Co-administration of specific drugs with TOLSURA may result in changes in the efficacy of itraconazole and/or the co-administered drug, life-threatening effects and/or sudden death. <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1</linkHtml>, <linkHtml href="#S7.2">7.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="f68dd9d0-8969-45d0-a895-6460422b42a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Peripheral Neuropathy</title>
                     <text>
                        <paragraph>Cases of peripheral neuropathy have been reported in patients on long-term therapy with itraconazole. Monitor for and promptly evaluate neurologic symptoms. If neuropathy attributable to TOLSURA occurs, discontinue treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="c0aaf283-9ceb-4f67-b270-c949d8992772"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Hearing Loss</title>
                     <text>
                        <paragraph>Reversible or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S4.2">Contraindications (4.2)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. The hearing loss usually resolves when treatment is stopped but can persist in some patients.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="efa61186-f90e-4063-a200-f6c107cd4ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>TOLSURA is contraindicated in patients with a known hypersensitivity to itraconazole <content styleCode="italics">[see <linkHtml href="#S4.2">Contraindications (4.2)</linkHtml>].</content> Hypersensitivity reactions have been reported with the use of itraconazole <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>. Due to the limited information regarding cross-hypersensitivity between itraconazole and other azole antifungal drugs, careful enquiry about previous hypersensitivity to other azole antifungal drugs should be made when prescribing TOLSURA. If hypersensitivity reactions to TOLSURA occurs, discontinue the drug and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="cd519894-8365-404c-b3bf-5b4a08622117"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Congestive Heart Failure <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Cardiac Dysrhythmias <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Pseudoaldosteronism <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Peripheral Neuropathy <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Hearing Loss <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence ≥ 1%) are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, hypertension, abnormal hepatic function, abdominal pain, dizziness, hypokalemia, anorexia, malaise, decreased libido, somnolence, albuminuria, impotence (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="c3606a31-609b-43a0-91bf-2c153931936a"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="79748433-75d3-458f-8500-720f309dca43"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in the Treatment of Systemic Fungal Infections</content>
                              </paragraph>
                              <paragraph>Safety data with itraconazole capsules were derived from 602 patients treated for systemic fungal disease in U.S. clinical trials who were immunocompromised or receiving multiple concomitant medications. Treatment was discontinued in 10.5% of patients due to adverse events. The median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). Table 2 lists adverse reactions reported by at least 1% of patients.</paragraph>
                              <table width="75%">
                                 <caption>Table 2: Clinical Trials of Systemic Fungal Infections: Adverse Reactions Occurring with an Incidence of ≥1%</caption>
                                 <col width="60%" align="left" valign="top"/>
                                 <col width="40%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body System/Adverse Reaction</th>
                                       <th styleCode="Rrule">Incidence (%) (N=602)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">11</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Abdominal Pain</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anorexia</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body as a Whole</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Edema</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Fever</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Malaise</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Skin and Appendages</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Rash<footnote ID="foot21">Rash tends to occur more frequently in immunocompromised patients receiving immunosuppressive medications.</footnote>
                                       </td>
                                       <td styleCode="Rrule">9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Central/Peripheral Nervous System</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Psychiatric</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Libido Decreased</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Somnolence</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Cardiovascular</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypertension</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolic/Nutritional</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypokalemia</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Urinary System</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Albuminuria</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Liver and Biliary System</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hepatic Function Abnormal</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Reproductive System, Male</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Impotence</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Adverse reactions reported at a rate of &lt;1% included: constipation, gastritis, depression, insomnia, tinnitus, menstrual disorder, adrenal insufficiency, gynecomastia, and male breast pain.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="edae337f-d7cd-400e-9965-e2524457cbdb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions Reported from Other Clinical Trials</content>
                              </paragraph>
                              <paragraph>In addition, the following adverse reactions were reported in itraconazole-treated patients who participated in clinical trials:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hepatobiliary Disorders:</content> hyperbilirubinemia;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiac Disorders:</content> cardiac failure, left ventricular failure, tachycardia;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">General Disorders and Administration Site Conditions:</content> face edema, chest pain, chills;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hepatobiliary Disorders:</content> hepatic failure, jaundice;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Investigations:</content> alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, blood urea increased, gammaglutamyltransferase increased, urine analysis abnormal;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Metabolism and Nutrition Disorders:</content> hyperglycemia, hyperkalemia, hypomagnesemia;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Psychiatric Disorders:</content> confusional state;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Renal and Urinary Disorders:</content> renal impairment;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders:</content> dysphonia, cough;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> hyperhidrosis;</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Vascular Disorders:</content> hypotension</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="89ea0dd0-53de-4e9e-9519-e6615fbd9939"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Adverse reactions that have been identified during post-marketing experience with itraconazole are listed in Table 3. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.</paragraph>
                        <table width="90%">
                           <caption>Table 3: Postmarketing Reports of Adverse Drug Reactions</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Blood and Lymphatic System Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Leukopenia, neutropenia, thrombocytopenia</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Immune System Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Anaphylaxis; anaphylactic, anaphylactoid and allergic reactions; serum sickness; angioneurotic edema</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Endocrine Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Pseudoaldosteronism</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Nervous System Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Peripheral neuropathy, paresthesia, hypoesthesia, tremor</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Eye Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Visual disturbances, including blurred vision and diplopia</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Ear and Labyrinth Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Transientor permanent hearing loss</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Pulmonary edema, dyspnea</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Pancreatitis, dysgeusia</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Hepatobiliary Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Serious hepatotoxicity (including some cases of fatal acute liver failure), hepatitis</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Skin and Subcutaneous Tissue Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity, urticaria</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Arthralgia</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Renal and Urinary Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Urinary incontinence, pollakiuria</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Reproductive System and Breast Disorders:</content>
                                 </td>
                                 <td styleCode="Rrule">Erectile dysfunction</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">General Disorders and Administration Site Conditions:</content>
                                 </td>
                                 <td styleCode="Rrule">Peripheral edema</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Investigations:</content>
                                 </td>
                                 <td styleCode="Rrule">Blood creatine phosphokinase increased</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="03e2c980-166c-41c8-8a9e-5d17c4351f63"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Itraconazole is mainly metabolized through CYP3A4. Other drugs that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5">5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="b46bb47e-fa29-4ea4-93b2-a415fadd51f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of TOLSURA on Other Drugs</title>
                     <text>
                        <paragraph>Itraconazole and its major metabolite, hydroxy-itraconazole, are potent CYP3A4 inhibitors. Itraconazole is an inhibitor of the drug transporters P-glycoprotein and breast cancer resistance protein (BCRP). Consequently, itraconazole has the potential to interact with many concomitant drugs resulting in either increased or sometimes decreased concentrations of the concomitant drugs. Increased concentrations may increase the risk of adverse reactions associated with the concomitant drug which can be severe or life-threatening in some cases (e.g., QT prolongation, <content styleCode="italics">Torsade de Pointes</content>, respiratory depression, hepatic adverse reactions, hypersensitivity reactions, myelosuppression, hypotension, seizures, angioedema, atrial fibrillation, bradycardia, priapism). Reduced concentrations of concomitant drugs may reduce their efficacy. Table 4 lists examples of drugs that may have their concentrations affected by itraconazole, but is not a comprehensive list. Refer to the approved product labeling to become familiar with the interaction pathways, risk potential, and specific actions to be taken with regards to each concomitant drug prior to initiating therapy with itraconazole.</paragraph>
                        <paragraph>Although many of the clinical drug interactions in Table 4 are based on information with a similar azole antifungal, ketoconazole, these interactions are expected to occur with itraconazole.</paragraph>
                        <table width="75%" ID="Table4">
                           <caption>Table 4: Drug Interactions with TOLSURA that Affect Concomitant Drug Concentrations</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th colspan="2" styleCode="Lrule Rrule">Concomitant Drug Within Class</th>
                                 <th styleCode="Rrule">Prevention or Management</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drug Interactions with TOLSURA that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Alpha Blockers</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Alfuzosin <br/>  Silodosin <br/>  Tamsulosin</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Analgesics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Methadone</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Fentanyl</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Alfentanil <br/>  Buprenorphine (IV and sublingual) <br/>  Oxycodone<footnote ID="foot41">Based on clinical drug interaction information with itraconazole.</footnote>
                                    <br/>  Sufentanil</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antiarrhythmics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Disopyramide <br/>  Dofetilide <br/>  Dronedarone <br/>  Quinidine<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Digoxin<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antibacterials</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Bedaquiline<footnote ID="foot42">Based on 400 mg Bedaquiline once daily for 2 weeks.</footnote>
                                 </td>
                                 <td styleCode="Rrule">Concomitant TOLSURA not recommended for more than 2 weeks at any time during bedaquiline treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Rifabutin</td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. See also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Clarithromycin</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary. See also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Trimetrexate</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticoagulants and Antiplatelets</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Ticagrelor</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Apixaban <br/>  Rivaroxaban <br/>  Vorapaxar</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Cilostazol <br/>  Dabigatran <br/>  Warfarin</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticonvulsants</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Carbamazepine</td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. See also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antidiabetic Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Repaglinide<footnoteRef IDREF="foot41"/>
                                    <br/>  Saxagliptin</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antihelminthics, Antifungals and Antiprotozoals</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Isavuconazonium</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Praziquantel</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Artemether-lumefantrine <br/>  Quinine<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antimigraine Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Ergot alkaloids (e.g., dihydroergotamine, ergotamine)</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Eletriptan</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antineoplastics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Irinotecan</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Axitinib <br/>  Bosutinib <br/>  Cabazitaxel <br/>  Cabozantinib <br/>  Ceritinib <br/>  Cobimetinib<footnoteRef IDREF="foot41"/>
                                    <br/>  Crizotinib <br/>  Dabrafenib <br/>  Dasatinib</td>
                                 <td styleCode="Rrule">Docetaxel <br/>  Ibrutinib <br/>  Lapatinib <br/>  Nilotinib <br/>  Olaparib<footnoteRef IDREF="foot41"/>
                                    <br/>  Pazopanib <br/>  Sunitinib <br/>  Trabectedin <br/>  Trastuzumab-­emtansine <br/>  Vinca alkaloids</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Bortezomib <br/>  Brentuximab-vedotin <br/>  Busulfan<footnoteRef IDREF="foot41"/>
                                    <br/>  Erlotinib <br/>  Gefitinib<footnoteRef IDREF="foot41"/>
                                    <br/>  Idelalisib <br/>  Imatinib <br/>  Ixabepilone</td>
                                 <td styleCode="Rrule">Nintedanib <br/>  Panobinostat <br/>  Ponatinib <br/>  Ruxolitinib <br/>  Sonidegib <br/>  Vandetanib<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary. For Idelalisib, see also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antipsychotics, Anxiolytics and Hypnotics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Alprazolam<footnoteRef IDREF="foot41"/>
                                    <br/>  Aripiprazole<footnoteRef IDREF="foot41"/>
                                    <br/>  Buspirone<footnoteRef IDREF="foot41"/>
                                    <br/>  Diazepam<footnoteRef IDREF="foot41"/>
                                    <br/>  Haloperidol<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Midazolam (IV)<footnoteRef IDREF="foot41"/>
                                    <br/>  Quetiapine <br/>  Ramelteon <br/>  Risperidone<footnoteRef IDREF="foot41"/>
                                    <br/>  Suvorexant</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Zopiclone<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Lurasidone <br/>  Midazolam (oral)<footnoteRef IDREF="foot41"/>
                                    <br/>  Pimozide <br/>  Triazolam<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antivirals</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Simeprevir</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Daclatasvir <br/>  Indinavir<footnoteRef IDREF="foot41"/>
                                    <br/>  Maraviroc</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary. For indinavir, see also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Cobicistat <br/>  Elvitegravir (ritonavir-boosted) <br/>  Ritonavir <br/>  Saquinavir (unboosted)<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. See also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Tenofovir disoproxil fumarate</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Beta Blockers</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Nadolol<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Calcium Channel Blockers</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Felodipine<footnoteRef IDREF="foot41"/>
                                    <br/>  Nisoldipine</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Diltiazem <br/>  Other dihydropyridines <br/>  Verapamil</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary. For diltiazem, see also <linkHtml href="#Table5">Table 5</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <paragraph ID="Cardio">
                                       <content styleCode="bold">Cardiovascular Drugs, Miscellaneous</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Ivabradine <br/>  Ranolazine</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Aliskiren<footnoteRef IDREF="foot41"/>
                                    <br/>  Riociguat <br/>  Sildenafil (for pulmonary hypertension) <br/>  Tadalafil (for pulmonary hypertension)</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment. For sildenafil and tadalafil, see also <linkHtml href="#Uro">Urologic Drugs</linkHtml> below.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Bosentan <br/>  Guanfacine</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Contraceptives</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Dienogest <br/>  Ulipristal</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Diuretics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Eplerenone</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Naloxegol</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Aprepitant <br/>  Loperamide<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Netupitant</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Immunosuppressants</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Everolimus <br/>  Sirolimus <br/>  Temsirolimus (IV)</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Budesonide (inhalation)<footnoteRef IDREF="foot41"/>
                                    <br/>  Budesonide (noninhalation) <br/>  Ciclesonide (inhalation) <br/>  Cyclosporine (IV)<footnoteRef IDREF="foot41"/>
                                    <br/>  Cyclosporine (non-IV) <br/>  Dexamethasone<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Fluticasone (inhalation)<footnoteRef IDREF="foot41"/>
                                    <br/>  Fluticasone (nasal) <br/>  Methylprednisolone<footnoteRef IDREF="foot41"/>
                                    <br/>  Tacrolimus (IV)<footnoteRef IDREF="foot41"/>
                                    <br/>  Tacrolimus (oral)</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Lipid-Lowering Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Lomitapide <br/>  Lovastatin<footnoteRef IDREF="foot41"/>
                                    <br/>  Simvastatin<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Atorvastatin<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for drug adverse reactions. Concomitant drug dose reduction may be necessary<sup>.</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Respiratory Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Salmeterol</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">SSRIs, Tricyclics and Related Antidepressants</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Venlafaxine</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <paragraph ID="Uro">
                                       <content styleCode="bold">Urologic Drugs</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Avanafil</td>
                                 <td styleCode="Rrule">Contraindicated during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Fesoterodine</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">Patients with moderate to severe renal or hepatic impairment</content>: Contraindicated during and 2 weeks after TOLSURA treatment. <br/>
                                    <content styleCode="italics">Other patients</content>: Monitor for adverse reactions. <br/>  Concomitant drug dose reduction may be necessary</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Solifenacin</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">Patients with severe renal or moderate to severe hepatic impairment</content>: Contraindicated during and 2 weeks after TOLSURA treatment. <br/>
                                    <content styleCode="italics">Other patients</content>: Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Darifenacin <br/>  Vardenafil</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Dutasteride <br/>  Oxybutynin<footnoteRef IDREF="foot41"/>
                                    <br/>  Sildenafil (for erectile dysfunction) <br/>  Tadalafil (for erectile dysfunction and benign prostatic hyperplasia) <br/>  Tolterodine</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary. For sildenafil and tadalafil, see also <linkHtml href="#Cardio">Cardiovascular Drugs</linkHtml> above.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td> </td>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Miscellaneous Drugs and Other Substances</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Colchicine</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">Patients with renal or hepatic impairment:</content> Contraindicated during and 2 weeks after TOLSURA treatment. <br/>
                                    <content styleCode="italics">Other patients</content>: Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Eliglustat</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">CYP2D6 EMs<footnote ID="foot43">EMs: extensive metabolizers; IMs: intermediate metabolizers, PMs: poor metabolizers.</footnote>taking a strong or moderate CYP2D6 inhibitor, CYP2D6 IMs<footnoteRef IDREF="foot43"/>, or CYP2D6 PMs<footnoteRef IDREF="foot43"/>
                                    </content>: Contraindicated during and 2 weeks after TOLSURA treatment. <br/>
                                    <content styleCode="italics">CYP2D6 EMs<footnoteRef IDREF="foot43"/>not taking a strong or moderate CYP2D6 inhibitor</content>: Monitor for adverse reactions. Eliglustat dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Lumacaftor/Ivacaftor</td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Alitretinoin (oral) <br/>  Cabergoline <br/>  Cannabinoids <br/>  Cinacalcet <br/>  Ivacaftor</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Vasopressin Receptor Antagonists</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Conivaptan <br/>  Tolvaptan</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drug Interactions with TOLSURA that Decrease Concomitant Drug Concentrations and May Reduce Efficacy of the Concomitant Drug</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antineoplastics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Regorafenib</td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="italics">Saccharomyces boulardii</content>
                                 </td>
                                 <td styleCode="Rrule">Not recommended during and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Nonsteroidal Anti-Inflammatory Drugs</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Lrule Rrule">Meloxicam<footnoteRef IDREF="foot41"/>
                                 </td>
                                 <td styleCode="Rrule">Concomitant drug dose increase may be necessary.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="58219a42-299d-4c0f-b11f-ef799e159ee5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of Other Drugs on TOLSURA</title>
                     <text>
                        <paragraph>Itraconazole is mainly metabolized through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Some concomitant drugs have the potential to interact with TOLSURA resulting in either increased or sometimes decreased concentrations of TOLSURA. Increased concentrations may increase the risk of adverse reactions associated with TOLSURA. Decreased concentrations may reduce TOLSURA efficacy.</paragraph>
                        <paragraph>Table 4 lists examples of drugs that may affect itraconazole concentrations, but is not a comprehensive list. Refer to the approved product labeling to become familiar with the interaction pathways, risk potential and specific actions to be taken with regards to each concomitant drug prior to initiating therapy with TOLSURA.</paragraph>
                        <paragraph>Although many of the clinical drug interactions in Table 5 are based on information with a similar azole antifungal, ketoconazole, these interactions are expected to occur with TOLSURA.</paragraph>
                        <table width="75%" ID="Table5">
                           <caption>Table 5: Drug Interactions with Other Drugs that Affect TOLSURA Concentrations</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Concomitant Drug Within Class</th>
                                 <th styleCode="Rrule">Prevention or Management</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drug Interactions with Other Drugs that Increase TOLSURA Concentrations and May Increase Risk of Adverse Reactions Associated with TOLSURA</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antibacterials</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Ciprofloxacin<footnote ID="foot51">Based on clinical drug interaction information with itraconazole. </footnote>
                                    <br/>  Erythromycin<footnoteRef IDREF="foot51"/>
                                    <br/>  Clarithromycin<footnoteRef IDREF="foot51"/>
                                 </td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. TOLSURA dose reduction may be necessary.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antineoplastics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Idelalisib</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. TOLSURA dose reduction may be necessary. See also <linkHtml href="#Table4">Table 4</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antivirals</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Cobicistat <br/>  Darunavir (ritonavir-boosted) <br/>  Elvitegravir (ritonavir-boosted) <br/>  Fosamprenavir (ritonavir-boosted) <br/>  Indinavir<footnoteRef IDREF="foot51"/>
                                    <br/>  Ritonavir <br/>  Saquinavir</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. TOLSURA dose reduction may be necessary. For, cobicistat, elvitegravir, indinavir, ritonavir, and saquinavir, see also <linkHtml href="#Table4">Table 4</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Calcium Channel Blockers</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Diltiazem</td>
                                 <td styleCode="Rrule">Monitor for adverse reactions. TOLSURA dose reduction may be necessary. See also <linkHtml href="#Table4">Table 4</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal Drugs</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Drugs that reduce gastric acidity e.g. acid neutralizing medicines such as aluminum hydroxide, or acid secretion suppressors such as H<sub>2</sub>- receptor antagonists and proton pump inhibitors (e.g., omeprazole).</td>
                                 <td styleCode="Rrule">Co-administration of these drugs, including omeprazole, with TOLSURA increases the systemic exposure to itraconazole. Monitor for adverse reactions. TOLSURA dose reduction may be necessary <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drug Interactions with Other Drugs that Decrease TOLSURA Concentrations and May Reduce Efficacy of TOLSURA</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antibacterials</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Isoniazid <br/>  Rifampicin<footnoteRef IDREF="foot51"/>
                                 </td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before and during TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Rifabutin<footnoteRef IDREF="foot51"/>
                                 </td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. See also <linkHtml href="#Table4">Table 4</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticonvulsants</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Phenobarbital <br/>  Phenytoin<footnoteRef IDREF="foot51"/>
                                 </td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before and during TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Carbamazepine</td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. See also <linkHtml href="#Table4">Table 4</linkHtml>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antivirals</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Efavirenz<footnoteRef IDREF="foot51"/>
                                    <br/>  Nevirapine<footnoteRef IDREF="foot51"/>
                                 </td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before and during TOLSURA treatment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Miscellaneous Drugs and Other Substances</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Lumacaftor/Ivacaftor</td>
                                 <td styleCode="Rrule">Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="1e488ce2-a3c1-4bce-b82e-5ec2fe06151b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="S8.1">
                     <id root="b392ec73-a8fe-4ef9-b741-67ae6eb6e91c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="727c7b82-aa2d-487a-9963-d8d75da534cc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on exposure to itraconazole during pregnancy for the approved indications. Published epidemiologic studies of women exposed to short courses of treatment with itraconazole in the first trimester of pregnancy have reported no risk of major birth defects overall and inconclusive findings on the risk of miscarriage <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>In animal reproduction studies, itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats at dosage levels of approximately (6-25 times the maximum recommended human dose [MRHD] of 390 mg/day based on mg/kg comparisons), and in mice at dosage levels of approximately 80 mg/kg/day (12 times the MRHD).</paragraph>
                              <paragraph>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="f55889b0-c5c7-4448-a78d-dc51d435f812"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section>
                                 <id root="347e7c28-41d4-4ba5-87c9-6abb23c0711f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Published prospective and retrospective cohort studies of women exposed to short courses of treatment with itraconazole in the first trimester of pregnancy (sample size 198-687) have reported no increase in the rate of major birth defects. The most important methodological limitation of these studies is the short duration of exposure in pregnancy (mean duration 6.9 to 8.5 days), or the lack of information on treatment duration. The risk of prolonged exposure in pregnancy is not known.</paragraph>
                                    <paragraph>Published prospective and retrospective cohort studies of pregnant women exposed to itraconazole (sample size 131-198) have reported inconsistent findings on the risk of miscarriage. Available data are inconclusive and limited by possible bias due to earlier enrollment and possible residual confounding in the exposed group compared to the unexposed group.</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="b4c18922-ca93-4cad-9b63-97190ea47e53"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Itraconazole has been shown to cross the placenta in a rat model. In animal reproduction studies, itraconazole administration to rats and mice during organogenesis resulted in maternal toxicity, embryotoxicity and teratogenicity at and above 40 and 80 mg/kg respectively (doses equivalent to 6- and 12-times the MRHD of 390 mg/day, based on mg/kg comparisons). In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of encephaloceles and/or macroglossia.</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="db0a7c2f-f3b3-4c22-a203-969d05c21a99"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="060c4028-03ff-4588-8870-bd47fb183d95"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Itraconazole is excreted in human milk; however, there are no data on the amount of itraconazole in human milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TOLSURA and any potential adverse effects on the breastfed child from TOLSURA or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="c3fe1d6b-3077-4ee8-98d5-557087eed86d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                        <paragraph>The long-term effects of itraconazole on bone growth in children are unknown. Bone lesions were observed in the young adult rats dosed with oral itraconazole for 3 to 12 months <content styleCode="italics">[see <linkHtml href="#S13.2">Nonclinical Toxicology (13.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="e5fe61b5-ddee-4982-a885-45105f346602"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of itraconazole did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. It is advised to use TOLSURA Capsules in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Reversible or permanent hearing loss has been reported in elderly patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6cec8702-33fc-4ef4-bdd9-e9e7dbdaa085"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Limited data are available on the use of oral itraconazole in patients with renal impairment. It is recommended that patients with renal impairment be carefully monitored when taking TOLSURA <content styleCode="italics">[see <linkHtml href="#S12">Clinical Pharmacology (12)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="916b2e73-489f-4812-8126-98b3eb43661f"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Limited data are available on the use of oral itraconazole in patients with hepatic impairment. It is recommended that patients with impaired hepatic function be carefully monitored when taking TOLSURA. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolized by CYP3A4 <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with TOLSURA is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. It is recommended that liver function monitoring be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications <content styleCode="italics">[see <linkHtml href="#S12">Clinical Pharmacology (12)</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="86ae186c-441a-43d7-9be6-87ac8ee63c9c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Itraconazole is not removed by dialysis. In the event of accidental overdosage, supportive measures should be employed. Activated charcoal may be given if considered appropriate.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="d791d498-c979-4976-808a-da318a68a168"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>TOLSURA (itraconazole capsules) is an azole antifungal drug for oral use. Itraconazole is an equal mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the following structural formula and nomenclature:</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="middle"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>(±)-1-[(<content styleCode="underline">R</content>*)-<content styleCode="underline">sec</content>-butyl]-4-[<content styleCode="underline">p</content>-[4-[<content styleCode="underline">p</content>-[[(2<content styleCode="underline">R</content>*,4<content styleCode="underline">S</content>*)-2-(2,4-dichlorophenyl)-2-(1<content styleCode="underline">H</content>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one mixture with (±)-1-[(<content styleCode="underline">R</content>*)-<content styleCode="underline">sec</content>-butyl]-4-[<content styleCode="underline">p</content>-[4-[<content styleCode="underline">p</content>-[[(2<content styleCode="underline">S</content>*,4<content styleCode="underline">R</content>*)-2-(2,4-dichlorophenyl)-2-(1<content styleCode="underline">H</content>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one</paragraph>
                  <paragraph>or</paragraph>
                  <paragraph>(±)-1-[(<content styleCode="underline">RS</content>)-<content styleCode="underline">sec</content>-butyl]-4-[<content styleCode="underline">p</content>-[4-[<content styleCode="underline">p</content>-[[(2<content styleCode="underline">R</content>,4<content styleCode="underline">S</content>)-2-(2,4-dichlorophenyl)-2-(1<content styleCode="underline">H</content>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one.</paragraph>
                  <paragraph>Itraconazole has a molecular formula of C<sub>35</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>8</sub>O<sub>4</sub> and a molecular weight of 705.64. It is a white to slightly yellowish powder. It is insoluble in water, very slightly soluble in alcohols, and freely soluble in dichloromethane. It has a pKa of 3.70 (based on extrapolation of values obtained from methanolic solutions) and a log (n-octanol/water) partition coefficient of 5.66 at pH 8.1.</paragraph>
                  <paragraph>Each TOLSURA capsule contains 65 mg of itraconazole dispersed in a polymer matrix and encapsulated in a hard gelatin capsule. The inactive ingredients are colloidal silicon dioxide, hypromellose phthalate, magnesium stearate and sodium starch glycolate.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tolsura-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="9c68114b-7b54-4024-8af7-ada8663c3e37"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="S12.1">
                     <id root="a159da6a-5d3b-43b2-a168-fceadab9fc2f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Itraconazole is an azole antifungal drug <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="0b2fbe77-8fdb-4cdd-a777-6f218e261237"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="d8a087db-14ab-4a7b-9dff-8c5fc8a5a380"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">General Pharmacokinetic Characteristics</content>
                              </paragraph>
                              <paragraph>The steady-state pharmacokinetics of itraconazole following administration of a 130 mg twice daily dose regimen of TOLSURA (2 × 65 mg) was compared with a 200 mg twice daily dose regimen of itraconazole capsules (2 × 100 mg) immediately after a meal for 14.5 days in 16 healthy volunteers; the results from this study are presented in Table 6 below</paragraph>
                              <table width="75%">
                                 <caption>Table 6: Pharmacokinetics of Itraconazole Following Administration of TOLSURA and Itraconazole Capsules Given Twice Daily for 14.5 Days Under Fed Conditions<footnote ID="foot61">Standardized high-fat, high-calorie breakfast was given 30 minutes prior to dosing on the morning of Day 15; standardized meals given prior to all other doses.</footnote> in 16 Healthy Subjects</caption>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="35%" align="center" valign="top"/>
                                 <col width="35%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Parameter<footnote ID="foot62">Geometric means ± standard deviation</footnote>
                                          <sup>,</sup>
                                          <footnote ID="foot63">T<sub>max</sub> presented as median (range)</footnote>
                                       </th>
                                       <th styleCode="Rrule">TOLSURA 130 mg twice daily <br/>(2 × 65 mg Capsules)</th>
                                       <th styleCode="Rrule">Itraconazole 200 mg twice daily <br/>(2 × 100 mg Capsules)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">AUC<sub>0-tau</sub>
                                          </content>
                                          <br/>  (hr*mcg/ml)</td>
                                       <td styleCode="Rrule">15.6 ± 3.7</td>
                                       <td styleCode="Rrule">14.9 ±3.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">C<sub>trough</sub>
                                          </content>
                                          <br/>  (mcg/ml)</td>
                                       <td styleCode="Rrule">1.2 ±0.4</td>
                                       <td styleCode="Rrule">1.0±0.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">C<sub>max,ss</sub>
                                          </content>
                                          <br/>  (mcg/ml)</td>
                                       <td styleCode="Rrule">1.6 ±0.4</td>
                                       <td styleCode="Rrule">1.5 ±0.4</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">T<sub>max,ss</sub>
                                          </content>
                                          <br/>  (h)</td>
                                       <td styleCode="Rrule">7.0 (1-10)</td>
                                       <td styleCode="Rrule">5.0 (1-8)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Peak plasma concentrations of itraconazole after administration of a single dose of TOLSURA are reached within 2 to 6 hours following oral administration in either the fasted or fed states. As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during multiple dosing of TOLSURA. Steady-state concentrations are generally reached within about 15 days, with mean C<sub>max</sub> values of 0.6 mcg/ml and 1.7 mcg/ml after oral administration of 130 mg once daily and 130 mg twice daily, respectively</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="aca324f4-49d4-4b09-992c-a6a4bdfa6492"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section>
                                 <id root="9e623dbd-931f-4268-9185-bb0d16b00242"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>The effect of food on the steady-state pharmacokinetics of itraconazole following administration of a 130 mg twice daily dose regimen of TOLSURA (2 × 65 mg) for 14.5 days under fed and fasted conditions was evaluated in 20 healthy volunteers. A high-fat meal with total caloric content of 919 calories (526 fat calories, 260 carbohydrate calories and 133 protein calories) was used in the study. The results are shown in Table 7 below.</paragraph>
                                    <table width="90%">
                                       <caption>Table 7: Pharmacokinetic Parameters of Itraconazole Following Administration of TOLSURA 130 mg (2 × 65 mg capsules) Given Twice Daily for 14.5 Days Under Fed and Fasted Conditions in 20 Healthy Subjects</caption>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Parameter</content>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Treatment</content>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Geometric Mean</content>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Fed/Fasted Ratio (%)</content>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">90% Confidence Interval</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">
                                                <content styleCode="bold">C<sub>max_ss</sub>
                                                </content>
                                                <br/>  (mcg/mL)</td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fed</content>
                                             </td>
                                             <td styleCode="Rrule">1.4 ± 0.6</td>
                                             <td styleCode="Rrule">73.7</td>
                                             <td styleCode="Rrule">69.0, 77.3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fasted</content>
                                             </td>
                                             <td styleCode="Rrule">1.9 ± 0.9</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">
                                                <content styleCode="bold">C<sub>trough,ss</sub>
                                                </content>
                                                <br/>  (mcg/mL)</td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fed</content>
                                             </td>
                                             <td styleCode="Rrule">1.0 ± 0.3</td>
                                             <td styleCode="Rrule">90.0</td>
                                             <td styleCode="Rrule">86.4, 97.0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fasted</content>
                                             </td>
                                             <td styleCode="Rrule">1.1 ± 0.6</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">
                                                <content styleCode="bold">AUC<sub>tau</sub>
                                                </content>
                                                <br/>  (hr*mcg/mL)</td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fed</content>
                                             </td>
                                             <td styleCode="Rrule">13.4 ± 5.0</td>
                                             <td styleCode="Rrule">78.4</td>
                                             <td styleCode="Rrule">74.5, 81.9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fasted</content>
                                             </td>
                                             <td styleCode="Rrule">17.1 ± 8.0</td>
                                             <td colspan="2" styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule"/>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Median</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Range</content>
                                             </td>
                                             <td rowspan="3" styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">
                                                <content styleCode="bold">T<sub>max</sub>
                                                </content>
                                                <br/>  (hr)</td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fed</content>
                                             </td>
                                             <td styleCode="Rrule">4.00</td>
                                             <td styleCode="Rrule">0.5 to 10</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Fasted</content>
                                             </td>
                                             <td styleCode="Rrule">3.50</td>
                                             <td styleCode="Rrule">0.5 to 5</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9b7ded96-6185-4310-ad0b-0c2d567d67e2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Most of the itraconazole in plasma is bound to protein (99.8%), with albumin being the main binding component (99.6% for the hydroxy-metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (&gt;700 L), suggesting extensive distribution into tissues. Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher. Concentrations in the cerebrospinal fluid are much lower than in plasma.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fc799de1-f7ed-4a0b-bff9-f04a6fa563fc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The terminal half-life of itraconazole following repeated dose administration of TOLSURA ranges between 34 to 42 hours under fed conditions.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="24422bbd-772d-4db2-bbc1-06b55db81ffb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>Itraconazole is extensively metabolized by the liver into a large number of metabolites. <content styleCode="italics">In vitro</content> studies have shown that CYP3A4 is the major enzyme involved in the metabolism of itraconazole. The main metabolite is hydroxy-itraconazole, which has in vitro antifungal activity comparable to itraconazole; trough plasma concentrations of this metabolite are about twice those of itraconazole.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4b666105-04c8-41c0-86b1-1fe1b4dc378f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Excretion</content>
                              </paragraph>
                              <paragraph>Itraconazole is excreted mainly as inactive metabolites in urine (35%) and in feces (54%) within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxyitraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabeled dose, fecal excretion of unchanged drug ranges from 3% to 18% of the dose.</paragraph>
                              <paragraph>As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin - where itraconazole can be detected as early as 1 week after start of treatment - for at least six months after the end of a 3-month treatment period.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9692dfe1-40b6-493f-8bd7-063ba62ec079"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section>
                                 <id root="ccbad521-9dd5-4113-97f0-c598ef45e8c1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Limited data are available on the use of oral itraconazole in patients with renal impairment. A pharmacokinetic study using a single 200-mg oral dose of itraconazole was conducted in three groups of patients with renal impairment (uremia: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of 13 mL/min. × 1.73 m<sup>2</sup>, the exposure, based on AUC, was slightly reduced compared with normal population parameters. This study did not demonstrate any significant effect of hemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (t<sub>max</sub>, C<sub>max</sub>, and AUC<sub>0-8h</sub>). Plasma concentration versus-time profiles showed wide intersubject variation in all three groups. After a single intravenous versus-time profiles showed wide intersubject variation in all three groups.</paragraph>
                                    <paragraph>After a single intravenous dose, the mean terminal half-lives of itraconazole in patients with mild (defined in this study as CrCl 50-79 ml/min), moderate (defined in this study as CrCl 20-49 ml/min), and severe renal impairment (defined in this study as CrCl &lt;20 ml/min) were similar to that in healthy subjects (range of means 42-49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). Overall exposure to itraconazole, based on AUC, was decreased in patients with moderate and severe renal impairment by approximately 30% and 40%, respectively, as compared with subjects with normal renal function. Data are not available in renally impaired patients during long-term use of itraconazole. Dialysis has no effect on the half-life or clearance of itraconazole or hydroxy-itraconazole.</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0467c09a-8a1a-46bd-bb5a-653f16b065e6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Itraconazole is predominantly metabolized in the liver. A pharmacokinetic study was conducted in 6 healthy and 12 cirrhotic subjects who were administered a single 100-mg dose of itraconazole capsules. A statistically significant reduction in mean C<sub>max</sub> (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. Data are not available in cirrhotic patients during long-term use of itraconazole.</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d2f870c3-4bd3-473c-b880-df6101bb815e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section>
                                 <id root="ff0025cc-7657-4314-8457-2d48dc9055f5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Omeprazole</content>
                                    </paragraph>
                                    <paragraph>The effect of multiple daily oral 40 mg doses (steady-state conditions) of the proton pump inhibitor, omeprazole, on the exposure to itraconazole from a single 130 mg dose of TOLSURA (2 × 65 mg capsules) when dosed under fasted conditions was evaluated in 30 healthy adult subjects. As illustrated in Table 8 below, the mean itraconazole AUC<sub>∞</sub> was 22% higher and mean C<sub>max</sub> 31% higher when TOLSURA was co-administered with omeprazole.</paragraph>
                                    <table width="75%">
                                       <caption>Table 8: Pharmacokinetics of Itraconazole Following Single Dose Administration of TOLSURA 130 mg (2 × 65mg capsules) Alone or with Omeprazole 40 mg QD Administered for 7 Days Under Fasted Conditions in Healthy Volunteers</caption>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Parameter</th>
                                             <th styleCode="Rrule">Treatment A<footnote ID="foot81">Treatment A: TOLSURA </footnote>
                                                <br/>Mean ±SD</th>
                                             <th styleCode="Rrule">Treatment A + B<footnote ID="foot82">Treatment B: Omeprazole</footnote>
                                                <br/>Mean ±SD</th>
                                             <th styleCode="Rrule">Treatment A+B vs Treatment A<br/>Ratio %</th>
                                             <th styleCode="Rrule">90% Confidence Interval</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">AUC<sub>∞</sub>
                                                </content>
                                                <br/>(h∙ng/mL)</td>
                                             <td styleCode="Rrule">2846.3 ±1644.4</td>
                                             <td styleCode="Rrule">3477.9 ± 1572.6</td>
                                             <td styleCode="Rrule">122.2</td>
                                             <td styleCode="Rrule">108.7, 137.3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">C<sub>max</sub>
                                                </content>
                                                <br/>(ng/mL)</td>
                                             <td styleCode="Rrule">212.9 ± 119.1</td>
                                             <td styleCode="Rrule">278.8 ±106.8</td>
                                             <td styleCode="Rrule">130.9</td>
                                             <td styleCode="Rrule">111.4, 153.8</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">T<sub>max</sub>
                                                   <footnote ID="foot83">T<sub>max</sub> is given as median (Range)</footnote>
                                                </content>
                                                <br/>(h)</td>
                                             <td styleCode="Rrule">3.5 <br/>(2.0 -5.0)</td>
                                             <td styleCode="Rrule">3.3 <br/>(1.5 – 5.0)</td>
                                             <td styleCode="Rrule">-</td>
                                             <td styleCode="Rrule">-</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="3d8817b0-0605-4474-9539-f54390d95fc9"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="cd706f8e-ba04-4191-b66c-b990ce5f7d32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent, <sup>14</sup>C-demethylation of ergosterol, which is a vital component of fungal cell membranes.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4fcdb1d5-8fcc-406b-a13a-792edd63cbee"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                              <paragraph>Isolates from several fungal species with decreased susceptibility to itraconazole have been isolated <content styleCode="italics">in vitro</content> and from patients receiving prolonged therapy. Several <content styleCode="italics">in vitro</content> studies have reported that some fungal clinical isolates with reduced susceptibility to one azole antifungal agent may also be less susceptible to other azole derivatives. The finding of cross-resistance is dependent on a number of factors, including the species evaluated, its clinical history, the particular azole compounds compared, and the type of susceptibility test performed.</paragraph>
                              <paragraph>Itraconazole is not active against <content styleCode="italics">Zygomycetes</content> (e.g., <content styleCode="italics">Rhizopus</content> spp., <content styleCode="italics">Rhizomucor</content> spp., <content styleCode="italics">Mucor</content> spp. and <content styleCode="italics">Absidia</content> spp.), <content styleCode="italics">Fusarium</content> spp., <content styleCode="italics">Scedosporium</content> spp. and <content styleCode="italics">Scopulariopsis</content> spp.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3dd298fe-a3de-47d2-86e2-f7c43f060d9d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Interaction with Other Antimicrobials</content>
                              </paragraph>
                              <paragraph>Studies (both <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content>) suggest that the activity of amphotericin B may be suppressed by prior azole antifungal therapy. Ergosterol is the active site for amphotericin B. In one study, the antifungal activity of amphotericin B against <content styleCode="italics">Aspergillus fumigatus</content> infections in mice was inhibited by ketoconazole therapy. The clinical significance of this finding is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b5f980bb-41d7-4fcc-9ec0-e469371760b8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antifungal Activity</content>
                              </paragraph>
                              <paragraph>Itraconazole exhibits <content styleCode="italics">in vitro</content> activity against <content styleCode="italics">Blastomyces dermatitidis, Histoplasma capsulatum, Histoplasma duboisii, Aspergillus flavus, Aspergillus fumigatus,</content> and <content styleCode="italics">Trichophyton</content> species <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content>. Correlation between minimum inhibitory concentration (MIC) results <content styleCode="italics">in vitro</content> and clinical outcome has yet to be established for azole antifungal agents.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="081b0473-141f-4156-9d3c-5511f5753451"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="S13.1">
                     <id root="1eb0323e-25e6-4412-b59a-b90a61704d4d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="0967b131-7c00-43bd-b91b-c1cc35632e2d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Itraconazole showed no evidence of carcinogenicity potential in mice treated orally for 23 months at dosage levels up to 80 mg/kg/day (approximately 12×MRHD, based on mg/kg comparisons). Male rats treated with 25 mg/kg/day (4×MRHD) had a slightly increased incidence of soft tissue sarcoma. These sarcomas may have been a consequence of hypercholesterolemia, which is a response of rats, but not dogs or humans, to chronic itraconazole administration. Female rats treated with 50 mg/kg/day (8×MRHD) had an increased incidence of squamous cell carcinoma of the lung (2/50) as compared to the untreated group. Although the occurrence of squamous cell carcinoma in the lung is extremely uncommon in untreated rats, the increase in this study was not statistically significant.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="93ee7705-3804-4203-8778-942606ebcbd7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Itraconazole produced no mutagenic effects when assayed in DNA repair test (unscheduled DNA synthesis) in primary rat hepatocytes, in Ames tests with <content styleCode="italics">Salmonella typhimurium</content> (6 strains) and <content styleCode="italics">Escherichia coli</content>, in the mouse lymphoma gene mutation tests, in a sex-linked recessive lethal mutation (<content styleCode="italics">Drosophila melanogaster</content>) test, in chromosome aberration tests in human lymphocytes, in a cell transformation test with C3H/10T½ C18 mouse embryo fibroblasts cells, in a dominant lethal mutation test in male and female mice, and in micronucleus tests in mice and rats.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="03e3e52d-2b11-4de0-8226-b4df59fb08d3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Itraconazole did not affect the fertility of male or female rats treated orally with dosage levels of up to 40 mg/kg/day (6×MRHD, based on mg/kg comparisons), even though parental toxicity was present at this dosage level.</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="8ded306d-2cf9-46a0-99ef-0d32a4ca5247"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented.</paragraph>
                        <paragraph>In three toxicology studies using rats, itraconazole (dosed in feed or via oral gavage) induced bone defects at dosage levels as low as 20 mg/kg/day (3×MRHD, based on mg/kg comparisons). The induced defects included reduced bone plate activity, thinning of the zona compacta of the large bones, and increased bone fragility. At a dosage level of 80 mg/kg/day (12×MRHD) over 1 year or 160 mg/kg/day (25×MRHD) for 6 months, itraconazole induced small tooth pulp with hypocellular appearance in some rats.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="8f3c9768-e2e8-4fc2-bf94-2dba97fd13e7"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="72cd2604-14e4-4e9d-8af1-60a0c1ab473e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Overview of the Clinical Studies</content>
                        </paragraph>
                        <paragraph>Clinical studies in invasive mycoses listed in this section were conducted with itraconazole 100 mg capsules. Dosage for TOLSURA is different from that of other itraconazole formulations. TOLSURA is not interchangeable or substitutable with other itraconazole products <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>, <linkHtml href="#S2">Dosage and Administration (2)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.1">
                     <id root="536a3e9e-329c-4898-8502-e9d1c5cc49c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Blastomycosis</title>
                     <text>
                        <paragraph>Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status treated with the100 mg itraconazole capsules. The median dose was 200 mg/day (2 × 100 mg). A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="5e5ad467-de0a-4e83-994a-d7d8392e81d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Histoplasmosis</title>
                     <text>
                        <paragraph>Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients) treated with the 100 mg itraconazole capsules. The median dose was 200 mg/day (2 × 100 mg). A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="ef77e492-9306-411c-8508-717cc4141eed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Histoplasmosis in HIV-infected Patients</title>
                     <text>
                        <paragraph>Data from a small number of HIV-infected patients treated with the 100 mg itraconazole capsules suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="8a72d6c5-ba1a-47e1-8411-36a6e83e18d8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Aspergillosis</title>
                     <text>
                        <paragraph>Analyses were conducted on data from an open-label, "single-patient-use" protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 (2 × 100 mg) to 400 (4 × 100 mg) mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of the 100 mg itraconazole capsules as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="a3233c6a-f891-4f63-8c57-0b1724678e60"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>TOLSURA (itraconazole capsules) is supplied in a size 1, hard gelatin capsules with light blue cap and white body, imprinted with "i-65" in black on the cap and containing 65 mg of itraconazole.</paragraph>
                  <paragraph>TOLSURA capsules are supplied as follows:</paragraph>
                  <table width="60%" styleCode="Noautorules">
                     <col width="40%" align="left" valign="top"/>
                     <col width="60%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles of 8 capsules</td>
                           <td>Bottles of 60 capsules</td>
                        </tr>
                        <tr>
                           <td>NDC 51862-462-88</td>
                           <td>NDC 51862-462-60</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="84de6195-a45b-4b5c-87a7-1452f905d1b6"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 25°C (77°F); excursions permitted 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light resistant container.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="64b56a11-ffa9-40f3-8eb7-e35e0b9e3807"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="cbcc7cc3-6fa8-4bff-8206-8b0e43e606d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Important Administration Instructions</content>
                        </paragraph>
                        <paragraph>Instruct the patients that TOLSURA:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cannot be interchanged or substituted with other itraconazole products.</item>
                           <item>Must be swallowed whole and administered with food.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ba5c8bef-681e-4174-a5f8-6ed6463c42c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Congestive Heart Failure</content>
                        </paragraph>
                        <paragraph>Inform patients about the signs and symptoms of congestive heart failure. Instruct them to discontinue TOLSURA and contact their healthcare provider immediately, if these signs or symptoms occur during TOLSURA administration <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7ed175d3-2963-445a-9029-77532719973b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatoxicity</content>
                        </paragraph>
                        <paragraph>Instruct patients to stop TOLSURA treatment immediately and contact their healthcare provider if any signs and symptoms suggestive of liver dysfunction develop. Such signs and symptoms may include unusual fatigue, anorexia, nausea and/or vomiting, jaundice, dark urine, or pale stools <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="794cf8bd-7959-4c4b-8663-2afe46a4159e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use with Proton Pump Inhibitors and Potential Drug Interactions</content>
                        </paragraph>
                        <paragraph>Advise patients to discuss with their physician the use of TOLSURA with proton pump inhibitors, such as omeprazole. Instruct patients to contact their physician before taking any other concomitant medications with TOLSURA to ensure there are no potential drug interactions <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1</linkHtml>, <linkHtml href="#S4.2">4.2)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S7.2">Drug interactions (7.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0c4192ff-bb17-47c5-a6a9-20c309bdb602"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hearing Loss</content>
                        </paragraph>
                        <paragraph>Instruct patients that hearing loss can occur with the use of TOLSURA. The hearing loss usually resolves when treatment is stopped but can persist in some patients. Advise patients to inform their healthcare provider if any hearing loss symptoms occur <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f5a2fe4b-3bf8-4ade-b0cc-67d9712dc8c2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Vision Problem</content>
                        </paragraph>
                        <paragraph>Instruct patients that dizziness or blurred/double vision can sometimes occur with TOLSURA. Advise patients that if they experience these dizziness or blurred/double vision, they should contact their healthcare provider, and instruct the patient not to drive or use machines <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a4f4ea52-6b73-4480-a674-661d1204d725"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b55172ca-da80-4cb6-9e6f-de4e84d65db8"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Mayne Pharma</content>
                  </paragraph>
                  <paragraph>Raleigh, NC 27609</paragraph>
                  <paragraph>TOLSURA is a registered trademark of Mayne Pharma.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5f882d43-61b1-433c-9ac3-d889b6fb2f79"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="3%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <col width="32%" align="left" valign="top"/>
                     <col width="32%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td colspan="5" align="left">This Patient Information has been approved by the U.S. Food and Drug Administration. <br/>  Issued: 10/2024</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td align="center" colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">Patient Information <br/>  TOLSURA (tol sur ah) <br/>  (itraconazole capsules)</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">Read this Patient Information that comes with TOLSURA before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule Rrule">
                              <paragraph ID="Important">
                                 <content styleCode="bold">What is the most important information I should know about TOLSURA? <br/>  TOLSURA can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>1.</caption>
                                    <content styleCode="bold">Congestive heart failure.</content> TOLSURA can cause congestive heart failure or make congestive heart failure that you already have worse. <content styleCode="bold">Stop taking TOLSURA and call your doctor right away if you have any of these symptoms of congestive heart failure:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>shortness of breath</item>
                                 <item>swelling of your feet, ankles or legs</item>
                                 <item>sudden weight gain</item>
                                 <item>increased tiredness</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>coughing up white or pink mucus (phlegm)</item>
                                 <item>fast heartbeat</item>
                                 <item>waking up at night more than normal for you</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <caption>2.</caption>
                                    <content styleCode="bold">Heart problems and other serious medical problems.</content> Serious medical problems that affect the heart and other parts of your body can happen if you take TOLSURA with certain other medicines.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Do not take TOLSURA if you take any of the following medicines:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>avanafil</item>
                                 <item>disopyramide</item>
                                 <item>dofetilide</item>
                                 <item>dronedarone</item>
                                 <item>eplerenone</item>
                                 <item>ergot alkaloids (such as dihydroergotamine or ergotamine)</item>
                                 <item>felodipine</item>
                                 <item>irinotecan</item>
                                 <item>isavuconazonium</item>
                                 <item>ivabradine</item>
                                 <item>lomitapide</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>lovastatin</item>
                                 <item>lurasidone</item>
                                 <item>methadone</item>
                                 <item>midazolam (taken by mouth)</item>
                                 <item>naloxegol</item>
                                 <item>nisoldipine</item>
                                 <item>pimozide</item>
                                 <item>quinidine</item>
                                 <item>ranolazine</item>
                                 <item>simvastatin</item>
                                 <item>ticagrelor</item>
                                 <item>triazolam</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not take TOLSURA if you have kidney or liver problems and take any of the following medicines:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>colchicine</item>
                                       <item>fesoterodine</item>
                                       <item>solifenacin</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not take TOLSURA:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>if you have been told that an enzyme in your body, called CYP2D6, breaks down (metabolizes) certain medicines in your body too slowly.</item>
                                       <item>if you are taking the medicine eliglustat <content styleCode="bold">and</content> are also taking a medicine that slows the rate that your body breaks down (metabolizes) certain other medicines (CYP2D inhibitor). Ask your doctor or pharmacist if you take any of these medicines.</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="4" styleCode="Rrule">
                              <content styleCode="bold">These are not complete lists of medicines that can interact with TOLSURA.</content> TOLSURA may affect the way other medicines work, and other medicines may affect how TOLSURA works. You can ask your pharmacist for a list of medicines that interact with TOLSURA. <br/>
                              <content styleCode="bold">Before you start taking TOLSURA, tell your doctor about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>  Before you start any new medicine, ask your doctor or pharmacist if it is safe to take it with TOLSURA <content styleCode="bold">or within 2 weeks after stopping treatment with TOLSURA.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <caption>3.</caption>
                                    <content styleCode="bold">Liver problems.</content> TOLSURA can cause serious liver problems which may be severe and lead to death. <content styleCode="bold">Stop taking TOLSURA and call your doctor right away if you have any of these symptoms of liver problems:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>unusual fatigue</item>
                                 <item>loss of appetite</item>
                                 <item>nausea or vomiting</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>your skin or the white part of your eyes turn yellow (jaundice)</item>
                                 <item>dark (tea-colored) urine</item>
                                 <item>light-colored stools (bowel movement)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">For more information about side effects, see "<content styleCode="bold">
                                 <linkHtml href="#Side">What are the possible side effects of TOLSURA?</linkHtml>
                              </content>"</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is TOLSURA?</content>
                              <br/>  TOLSURA is a prescription medicine used to treat the following fungal infections in adults: blastomycosis, histoplasmosis, and aspergillosis. <br/>  TOLSURA is not for use for the treatment of fungal infections of the toenails or fingernails (onychomycosis). <br/>  TOLSURA is not for use in place of other medicines that contain itraconazole. <br/>  It is not known if TOLSURA is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not take TOLSURA if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See "<content styleCode="bold">
                                       <linkHtml href="#Important">What is the most important information I should know about TOLSURA?</linkHtml>
                                    </content>"</item>
                                 <item>are allergic to itraconazole or any of the ingredients in TOLSURA. See the end of this Patient Information leaflet for a complete list of ingredients in TOLSURA.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking TOLSURA, tell your doctor about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have heart problems.</item>
                                 <item>have lung problems.</item>
                                 <item>have kidney problems.</item>
                                 <item>have liver problems.</item>
                                 <item>have had an allergic reaction to a medicine used to treat a fungal infection.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if TOLSURA will harm your unborn baby. Tell your doctor if you become pregnant during treatment with TOLSURA.</item>
                                 <item>are breastfeeding or plan to breastfeed. TOLSURA can pass into your breast milk. Talk to your doctor about the best way to feed your baby if you take TOLSURA.</item>
                              </list>
                              <content styleCode="bold">Before you start taking TOLSURA, tell your doctor about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>  Especially tell your doctor if you take:<list listType="unordered" styleCode="Disc">
                                 <item>a medicine to treat high blood pressure or certain other heart problems called a calcium channel blocker.</item>
                                 <item>a medicine to reduce acid in your stomach called a proton pump inhibitor, such as omeprazole.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take TOLSURA?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take TOLSURA exactly as prescribed by your doctor. Your doctor will tell you how much TOLSURA to take and when to take it.</item>
                                 <item>TOLSURA <content styleCode="bold">must</content> be taken with food.</item>
                                 <item>TOLSURA capsules <content styleCode="bold">must</content> be swallowed whole.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> chew, crush or break TOLSURA capsules.</item>
                                 <item>If you take too much TOLSURA, call your doctor or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I avoid while taking TOLSURA?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>TOLSURA can cause dizziness and vision problems. <content styleCode="bold">Do not</content> drive or operate machinery until you know how TOLSURA affects you. Tell your doctor if you get dizziness or vision problems.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule Rrule">
                              <paragraph ID="Side">
                                 <content styleCode="bold">What are the possible side effects of TOLSURA? <br/>  TOLSURA may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See "<content styleCode="bold">
                                       <linkHtml href="#Important">What is the most important information I should know about TOLSURA?</linkHtml>
                                    </content>"</item>
                                 <item>
                                    <content styleCode="bold">New or worsening high blood pressure and low potassium levels in your blood (pseudoaldosteronism).</content> Your healthcare provider should check your blood pressure and potassium levels.</item>
                                 <item>
                                    <content styleCode="bold">Nerve problems (neuropathy).</content> Nerve problems have happened in some people who have taken TOLSURA for longer than 3 months. Call your doctor right away if you have tingling or numbness in your hands or feet. Your doctor may stop your treatment with TOLSURA if you have nerve problems.</item>
                                 <item>
                                    <content styleCode="bold">Hearing loss.</content> Hearing loss can happen in some people who take TOLSURA. Hearing loss usually improves when treatment with TOLSURA is stopped, but hearing loss has been permanent in some people. Call your doctor if you have any changes in your hearing.</item>
                              </list>
                              <content styleCode="bold">The most common side effects of TOLSURA include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td/>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea</item>
                                 <item>rash</item>
                                 <item>vomiting</item>
                                 <item>swelling</item>
                                 <item>headache</item>
                                 <item>diarrhea</item>
                                 <item>fatigue</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>fever</item>
                                 <item>itching</item>
                                 <item>high blood pressure</item>
                                 <item>abnormal liver blood tests</item>
                                 <item>stomach pain</item>
                                 <item>dizziness</item>
                                 <item>low blood potassium levels</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>loss of appetite</item>
                                 <item>general feeling of discomfort</item>
                                 <item>decreased sex drive</item>
                                 <item>sleepiness</item>
                                 <item>elevated levels of a type of protein, called albumin, in your urine</item>
                                 <item>erectile dysfunction</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">These are not all the possible side effects of TOLSURA. <br/>  Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store TOLSURA?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store TOLSURA at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Keep TOLSURA in a tightly closed container.</item>
                                 <item>Keep TOLSURA away from light.</item>
                              </list>
                              <content styleCode="bold">Keep TOLSURA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of TOLSURA.</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TOLSURA for a condition for which it was not prescribed. Do not give TOLSURA to other people, even if they have the same symptoms that you have. It may harm them. <br/>  You can ask your doctor or pharmacist for information about TOLSURA that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td/>
                           <td/>
                           <td/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in TOLSURA? <br/>  Active ingredient:</content> itraconazole <br/>
                              <content styleCode="bold">Inactive ingredients:</content> colloidal silicon dioxide, hypromellose phthalate, magnesium stearate and sodium starch glycolate <br/>  Manufactured by: Mayne Pharma <br/>  For more information, go to www.maynepharma.com or call 1-844-825-8500</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b33acead-010d-444e-a839-c436f3978202"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 65 mg Capsule Bottle Label</title>
               <text>
                  <paragraph>NDC 51862-462-60</paragraph>
                  <paragraph>TOLSURA<sup>®</sup>
                     <br/>  (Itraconazole Capsules)</paragraph>
                  <paragraph>65 mg</paragraph>
                  <paragraph>Attention: Tolsura<sup>®</sup> is NOT<br/> interchangeable on a mg per mg basis<br/> with other formulations of itraconazole.</paragraph>
                  <paragraph>Rx Only <br/>  60 Capsules</paragraph>
                  <paragraph>mayne pharma</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 65 mg Capsule Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tolsura-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>